Early experimental studies have revealed that IL-2 may serve as a survival factor for B-cell CLL (B-CLL) through the enhancement of antiapoptotic proteins (15), although high-dose IL-2 has been investigated as a therapeutic strategy for patients with CLL (16). The gene discussed is IL2; the disease is B-cell chronic lymphocytic leukemia.